BRAF/MEK inhibitors use for pediatric gliomas; real world experience from a resource-limited country

IntroductionMost pediatric low-grade-gliomas (LGG) and some high-grade-gliomas (HGG) have alterations in the RAS/MAPK pathway. Promising high tumor response rates were achieved using BRAF/MEK inhibitors, however data on their use in low-middle-income-countries (LMICs) are limited.MethodsWe retrospec...

Szczegółowa specyfikacja

Opis bibliograficzny

Główni autorzy:	Dima Abu Laban, Abeer Alsharif, Maysa Al-Hussaini, Mouness Obeidat, Bayan Maraqa, Qasem Alzoubi, Awni Musharbash, Saad Jaddoua, Raed Ramlawi, Kawther Khaleifeh, Ahmad Kh. Ibrahimi, Nasim Sarhan, Eric Bouffet, Nisreen Amayiri
Format:	Artigo
Język:	Inglês
Wydane:	Frontiers Media S.A. 2024-09-01
Seria:	Frontiers in Oncology
Hasła przedmiotowe:	BRAF/MEK inhibitors dabrafenib trametinib low-middle-income countries (LMIC) targeted therapy glioma
Dostęp online:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1417484/full
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!